More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$5.00B
EPS
-0.47
P/E ratio
--
Price to sales
2.45
Dividend yield
--
Beta
-2.218661
Previous close
$18.65
Today's open
$18.59
Day's range
$17.74 - $18.61
52 week range
$10.65 - $24.43
show more
CEO
--
Employees
8000
Headquarters
Northridge, CA
Exchange
Nasdaq Global Select
Shares outstanding
281349931
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
MiniMed Launches MiniMed Flex Pump in Europe to Expand Diabetes Care
MMED launches compact Flex insulin pump in Europe, combining app-based control and SmartGuard technology to expand diabetes care portfolio and reach.
Zacks Investment Research • 4 hours ago

MiniMed: The Split-Off Hangover Is Hiding A Full-Stack Product Cycle
I see MiniMed Group shifting from share donor to share taker as split-off selling obscures its product-cycle progress. MMED's Q1 organic growth accelerated to 15.8%; new U.S. pump volumes rose over 20%, supporting a business with roughly 80% recurring revenue. Flex, the Fit patch pump, and Vivera could complete MMED's portfolio by late 2027, though regulatory, competitive, and separation risks remain.
Seeking Alpha • 13 hours ago

MiniMed Launches MiniMed Flex™, its Smallest and Most Discrete Insulin Pump, in Europe
New app-controlled pump aims to make diabetes management easier and combines dependable clinical performance with convenient design NORTHRIDGE, Calif., Nov. 17, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED) a global leader in diabetes technology, today began commercial shipments of the MiniMed Flex™ system across Europe, following an initial customer experience phase in select markets.
PRNewsWire • Nov 17, 2026

FDA Clears MiniMed Fit Tubeless Insulin Pump with Seven-Day Wear
MiniMed (NASDAQ:MMED) on Monday secured U.S. Food and Drug Administration clearance for MiniMed Fit, marking the company's debut in the tubeless insulin pump market with a device offering up to seven days of wear and a 300-unit insulin capacity.
Benzinga • Nov 16, 2026

FDA Clears MiniMed Fit™ -- World's First and Only Tubeless Insulin Pump with Up to Seven-Day Wear and Zero Interruptions
The only tubeless pump with no charging or cartridge changes for up to seven days, combined with a 300-unit insulin capacity and advanced insulin automation NORTHRIDGE, Calif., Nov. 16, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED) today announced U.S. Food and Drug Administration (FDA) clearance of MiniMed Fit™, the company's first tubeless insulin pump, offering people with diabetes a new differentiated option that combines up to seven days of wear, a 300-unit insulin capacity, app control and proven SmartGuard™ technology.
PRNewsWire • Nov 16, 2026

Short Interest Powder Kegs: 10 Stocks Bears Cannot Quit Buying
Bears are crowding into a small group of stocks, and one name has nearly its entire float sold short.
Benzinga • Nov 11, 2026

MiniMed to Participate in Upcoming Investor Conferences
NORTHRIDGE, Calif., Nov. 5, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that Chad Spooner, EVP, Chief Financial Officer, will discuss and answer questions on the company at the following investor conferences: 9th Annual Evercore Healthcare Conference Tuesday, December 1, 2026, at 10:50 a.m.
PRNewsWire • Nov 5, 2026

MiniMed to Announce Its Fiscal Year 2027 Second Quarter Financial Results
NORTHRIDGE, Calif., Nov. 4, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that it expects to report financial results on Tuesday, November 24, 2026, for its second quarter of fiscal year 2027, which ended on Friday, October 30, 2026.
PRNewsWire • Nov 4, 2026

MiniMed Appoints Dr. David Segal as Chief Medical Officer
NORTHRIDGE, Calif., Nov. 3, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced the appointment of David Segal, M.D.
PRNewsWire • Nov 3, 2026

MiniMed Announces Board of Directors for its Next Chapter as an Independent Company
Directors bring expertise across healthcare access, medtech, commercial and manufacturing operations and public-company governance as MiniMed begins its next chapter as an independent company focused on making every day a better day for people with diabetes. NORTHRIDGE, Calif.
PRNewsWire • Oct 15, 2026

¹ Disclosures

Open an M1 investment account to buy and sell MiniMed Group Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.